AdipoGen Life Sciences

anti-IL-33 (human), mAb (IL33305B)

CHF 295.00
In stock
AG-20A-0041-C05050 µgCHF 295.00
AG-20A-0041-C100100 µgCHF 400.00
More Information
Product Details
Synonyms Interleukin-33; IL-1F11; NF-HEV
Product Type Monoclonal Antibody
Properties
Clone IL33305B
Isotype Mouse IgG2aκ
Immunogen/Antigen Recombinant human IL-33.
Application

ELISA: (direct or indirect: 1:2'000-1:5'000)
Functional Application (Blocking)
Immunohistochemistry (paraffin sections (1:50-1:200))
Immunoprecipitation
Western blot: (1:2'000-1:5'000 using ECL. Suggested blocking and dilution buffer is PBST with 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at rooom temperature).
Optimal conditions should be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes human IL-33. Does not cross-react with mouse IL-33.

Purity Detail Protein G-affinity purified.
Concentration 1mg/ml
Formulation Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Isotype Negative Control

Mouse IgG2a Isotype Control

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30kDa human IL33 is converted by CASP1 to a 18kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.

Product References
  1. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis: G. Palmer, et al.; Arthritis & Rheum. 60, 738 (2009)
  2. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease: J. Chapuis, et al.; Mol. Psychiatry 14, 1004 (2009) (Supplement Information)
  3. Interleukin-33 is biologically active independently of caspase-1 cleavage: D. Talabot-Ayer, et al.; JBC 284, 19420 (2009)
  4. Cigarette smoke alters IL-33 expression and release in airway epithelial cells: E. Pace, et al.; Biochim. Biophys. Acta 1842, 1630 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.